Characteristics and racial variations of polypoidal choroidal vasculopathy in tertiary centers in the United States and United Kingdom

Table 4 Multiple linear regression of demographic and clinical variables: effect on best corrected visual acuity at last follow up in patients with polypoidal choroidal vasculopathy

Variables	Coefficients	Standard error	t Stat	p value	Lower 95%	Upper 95%
Age	−0.71	0.25	−2.89	0.005*	−1.21	−0.22
Gender^a	−10.75	5.19	−2.07	0.042*	−21.12	−0.39
Ethnicity^b
Asian	−9.424398	6.08	−1.55	0.16	−21.56	2.71
White	−18.07	6.18	−2.92	0.005*	−30.41	−5.73
Other	0.58	13.06	0.045	0.97	−25.51	26.67
Initial BCVA	0.58	0.14	4.27	<0.001*	0.31	0.85
Follow up	−0.25	0.095	−2.6	0.012*	−0.44	−0.06
Polyp location	−14.41	6.00	−2.4	0.02*	−26.39	−2.42
Lens status	−0.96	6.94	−0.14	0.89	−14.83	12.91
Treatment
PDT	−2.15	5.66	−0.38	0.71	−13.45	9.15
Focal laser	0.62	3.12	0.2	0.84	−5.61	6.84
Bevacizumab	1.94	0.96	2.03	0.05	0.034	3.85
Ranibizumab	0.65	0.4	1.64	0.11	−0.14	1.44
Aflibercept	0.60	0.79	0.76	0.45	−0.98	2.19

The dependent variable is best corrected visual acuity (BCVA) at last follow up visit documented as early treatment diabetic retinopathy study (ETDRS) letter count. The independent variables are age, gender, ethnicity, initial BCVA, follow up (months), polyp location, lens status, and different treatment modalities, including photodynamic therapy (PDT), focal laser, intravitreal injections with bevacizumab, ranibizumab, and aflibercept. R squared was 0.55 and adjusted R squared was 0.45
* Statistically significant p < 0.05
^aFemale was used as the reference group (dominant gender in our cohort)
^bBlack was used as the reference group (largest ethnic group in our cohort). All calculations were made based on a multivariate analysis model

ISSN: 2056-9920